Abstract 293P
Background
Cervical cancer is a global public health issue. Cisplatin-based chemoradiation is the standard treatment for locally advanced scenarios. However, the toxicity and prolonged infusion time associated with cisplatin necessitate the search for options that yield similar outcomes. The objective of this study will be to compare the effectiveness of carboplatin versus cisplatin in patients with locally advanced cervical cancer undergoing chemoradiation.
Methods
The current study is an observational, retrospective, longitudinal, and descriptive type of research. The sample consisted of 183 patients with locally advanced cervical cancer who underwent chemoradiation treatment at the National Institute of Neoplastic Diseases, Lima, Peru, in the years 2014-201.
Results
Ninety-five patients aged equal to or less than 50 years and 88 patients aged over 50 years were analyzed, corresponding to 52% and 48% of the sample, respectively. The squamous cell carcinoma subtype represented 90% of the sample (164 cases), and the most frequent stages were IIB and IIIC, at 64% and 27% respectively. The trend for complete responses was higher for cisplatin, 82% vs. 77% for carboplatin. Patients who received cisplatin experienced more adverse effects than those who received carboplatin; neutropenia, diarrhea, and vomiting were the most reported events. At a 5-year follow-up, there was a 41% reduction in the risk of recurrence for cisplatin treatment (p 0.055), with a hazard ratio for overall survival of 0.72. It was observed that those who achieved a complete response had better survival.
Conclusions
In summary, while cisplatin demonstrated greater efficacy in terms of overall survival, carboplatin stood out for its more favorable tolerance profile. This suggests that carboplatin could be a valid alternative for patients with a more delicate clinical condition who might face challenges with cisplatin-associated toxicity. These findings underscore the importance of considering both efficacy and tolerability when choosing the appropriate therapy for patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Valdiviezo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract